Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
ConjuChem Biotechnologies Inc is a Canada based biotechnology company. It is primarily engaged in the business of creating novel, next-generation medicines using long-acting therapeutic peptides. The company's compounds are bio-conjugation platforms called Drug Affinity Complex (DAC) and Preformed Conjugate-Drug Affinity Complex (PC-DAC). When applied to a given peptide, DAC and PC- DAC can create new drugs with similar therapeutic activities but with longer duration of activity and improved safety profiles. The group's pipeline includes CJC-1134-PC for the treatment of diabetes, PC-DAC Insulin for the treatment of diabetes and DAC HIV for treating HIV.
Montreal, QC, H2X 3Y8, Canada